A practical reference on 冻干粉: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
More surface area Small volume The higher the surface area and volume, the particles become stronger, more stable and durable Materials may change electrical, optical, physical, chemical, or biological properties at the nano level Makes chemical and biological reactions easier Current commercial water purifiers using nanotechnology include the LifeSaver bottle, Lifesaver Jerrycan, Lifesaver Cube, Nanoceram, and NanoH2O.
On January 26, 2016, Kennedy launched a third bid for a Senate seat. In seeking to succeed the retiring Vitter, he faced more than 20 opponents. Vitter had announced his forthcoming retirement from the Senate in 2015 after losing a bid for governor to John Bel Edwards. Kennedy's senatorial campaign was endorsed by the U.S. Chamber of Commerce, the National Federation of Independent Business, the NRA Political Victory Fund, the National Right to Life Committee, the American Conservative Union, Vice President-elect Mike Pence and President-elect Donald Trump. Kennedy, who had supported Vitter for governor the previous year, won the jungle primary and faced Democrat Foster Campbell in a December 10 runoff election. President-elect Donald Trump—who had received Kennedy's support in the 2016 presidential election—campaigned for Kennedy the day before the runoff. Kennedy defeated Campbell by 536,204 votes (61%) to 347,813 (39%). He lost the most-populated parishes of Orleans and East Baton Rouge, in which he had been reared, but was a runaway winner in Campbell's home parish of Bossier.
=== Obesity and other hyperalimentation === 278 Obesity and other hyperalimentation 278.0 Obesity, NOS 278.1 Localized adiposity 278.2 Hypervitaminosis A 278.3 Hypercarotenemia 278.4 Hypervitaminosis D
The venous system is the system of veins in the systemic and pulmonary circulations that return blood to the heart. In the systemic circulation the return is of deoxygenated blood from the organs and tissues of the body, and in the pulmonary circulation the pulmonary veins return oxygenated blood from the lungs to the heart. Almost 70% of the blood in the body is in the veins, and almost 75% of this blood is in the small veins and venules. All of the systemic veins are tributaries of the largest veins, the superior and inferior vena cava, which empty the oxygen-depleted blood into the right atrium of the heart. The thin walls of the veins, and their greater internal diameters (lumens) enable them to hold a greater volume of blood, and this greater capacitance gives them the term of capacitance vessels. This characteristic also allows for the accommodation of pressure changes in the system. The whole of the venous system, bar the post-capillary venules is a large volume, low pressure system. The venous system is often asymmetric, and whilst the main veins hold a relatively constant position, unlike arteries, the precise location of veins varies among individuals.
Sources: en.wikipedia.org
In enzymology, an aromatic 2-oxoacid reductase (EC 1.1.1.110, previously indolelactate dehydrogenase) is an enzyme that catalyzes the reversible oxidation and reduction of aryllactate compounds to arylpyruvate compounds using the redox cofactor nicotinamide adenine dinucleotide or the similar nicotinamide adenine dinucleotide phosphate. For example, the enzyme may oxidize (R)-3-(4-hydroxyphenyl)lactate to 3-(4-hydroxyphenyl)pyruvic acid.
=== Immunophenotyping === Basophils of mice and humans have consistent immunophenotypes, including FcεRI+, CD123, CD49b(DX-5)+, CD69+, Thy-1.2+, 2B4+, CD11bdull, CD117(c-kit)−, CD24−, CD19−, CD80−, CD14−, CD23−, Ly49c−, CD122−, CD11c−, Gr-1−, NK1.1−, B220−, CD3−, γδTCR−, αβTCR−, α4 and β4-integrin negative. Recently, Heneberg proposed that basophils may be defined as the cellular population positive for CD13, CD44, CD54, CD63, CD69, CD107a, CD123, CD164, CD193/ CCR3, CD203c, TLR-4, and FcεRI. When activated, some additional surface markers are known to be upregulated (CD13, CD107a, CD164), or surface-exposed (CD63, and the ectoenzyme CD203c).
== Legal implications == At common law, in general, a myocardial infarction is a disease but may sometimes be an injury. This can create coverage issues in the administration of no-fault insurance schemes such as workers' compensation. In general, a heart attack is not covered; however, it may be a work-related injury if it results, for example, from unusual emotional stress or unusual exertion. In addition, in some jurisdictions, heart attacks had by persons in particular occupations such as police officers may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person having had an MI may be prevented from participating in activity that puts other people's lives at risk, for example driving a car or flying an airplane.
== Interactions == The drug transfers into breast milk. There is no evidence that its use during pregnancy is harmful to the developing fetus and its use is not contraindicated in pregnancy. The concurrent use of hydroxychloroquine and the antibiotic azithromycin appears to increase the risk for certain serious side effects with short-term use, such as an increased risk of chest pain, congestive heart failure, and mortality from cardiovascular causes. Care should be taken if combined with medication altering liver function as well as aurothioglucose (Solganal), cimetidine (Tagamet) or digoxin (Lanoxin). Hydroxychloroquine can increase plasma concentrations of penicillamine which may contribute to the development of severe side effects. It enhances hypoglycemic effects of insulin and oral hypoglycemic agents. Dose altering is recommended to prevent profound hypoglycemia. Antacids may decrease the absorption of hydroxychloroquine. Both neostigmine and pyridostigmine antagonize the action of hydroxychloroquine. While there may be a link between hydroxychloroquine and hemolytic anemia in those with glucose-6-phosphate dehydrogenase deficiency, this risk may be low in those of African descent. Specifically, the US Food and Drug Administration's (FDA) drug label for hydroxychloroquine lists the following drug interactions:
==== Mechanical injury ==== Direct pressure can physically deform the structure of the nerve. Local pressure can create a bidirectional displacement of nerve tissue from away from the area of compression by squishing the compressed tissue outwards. Studies using a cuff to compress a nerve have found the earliest and most severe injuries at the edge of the cuff, and this is called the "edge effect". The physical basis for the edge effect is believed to be a pressure gradient that deforms and then injures nerve tissue, and the pressure gradient is highest at the edges. At a microscopic level, intraneural blood vessels and nerve fibers are displaced longitudinally by shear strain. Surprisingly, smaller nerve fibers are more resistant to compression than large nerve fibers.
Sources: en.wikipedia.org
LECT2 Amyloidosis (ALECT2) is a form of amyloidosis caused by the LECT2 protein. It was found to be the third most common (~3% of total) cause of amyloidosis in a set of more than 4,000 individuals studied at the Mayo Clinic; the first and second most common forms the disorder were AL amyloidosis and AA amyloidosis, respectively. Amyloidosis is a disorder in which the abnormal deposition of a protein in organs and/or tissues gradually leads to organ failure and/or tissue injury. Although more than 30 different proteins can cause amyloidosis, the disorder caused by LECT2 is distinctive in three ways. First, it has an unusually high incidence in certain ethnic populations. Second, it is a systemic form of amyloidosis (i.e. amyloid deposited in multiple organs), as opposed to a localized form (amyloid deposits limited to a single organ) but nonetheless injures the kidney without or rarely injuring the other organs in which it is deposited. Third, LECT2 amyloidosis is diagnosed almost exclusively in elderly individuals. Given its relatively recent discovery, exceptionally strong ethnic bias, limitation to causing kidney disease, and restriction to elderly individuals, LECT2 amyloidosis appears at present to be an under-recognized cause of chronic kidney disease particularly in the ethnic groups that exhibit a high incidence of the disorder.
XLI Army Corps (mot.): 1st Panzer Division, 6th Panzer Division, 36th Motorised Infantry Division, 269th Infantry Division XXXXI Army Corps (mot.): 8th Panzer Division, 3rd Motorised Infantry Division, 290th Infantry Division 3rd SS Motorised Infantry Division Totenkopf 2nd SS Motorised Infantry Division Das Reich (during Operation Typhoon) The Army Group was to advance through the Baltic States to Leningrad. Barbarossa commenced on 22 June 1941 with a massive German attack along the whole front line. The 4th Panzer Group headed for the Dvina River to secure the bridges near the town of Daugavpils. The Red Army mounted a number of counterattacks against the XXXXI Panzer Corps, leading to the Battle of Raseiniai. After Reinhardt's corps closed in, the two corps were ordered to encircle the Soviet formations around Luga. Again having penetrated deep into the Soviet lines with unprotected flanks, Manstein's corps was the target of a Soviet counteroffensive from 15 July at Soltsy by the Soviet 11th Army. Manstein's forces were badly mauled and the Red Army halted the German advance at Luga. Ultimately, the army group defeated the defending Soviet Northwestern Front, inflicting over 90,000 casualties and destroying more than 1,000 tanks and 1,000 aircraft, then advanced northeast of the Stalin line. On 6 July 1941, Hoepner issued an order to his troops instructing them to treat the "loyal population" fairly, adding that "individual acts of sabotage should simply be charged to communists and Jews".
Complete blood count and reticulocyte count; in active G6PD deficiency, Heinz bodies can be seen in red blood cells on a blood film; Liver enzymes (to exclude other causes of jaundice); Lactate dehydrogenase (elevated in hemolysis and a marker of hemolytic severity) Haptoglobin (decreased in hemolysis); A "direct antiglobulin test" (Coombs' test) – this should be negative, as hemolysis in G6PD is not immune-mediated; When there are sufficient grounds to suspect G6PD, a direct test for G6PD is the "Beutler fluorescent spot test", which has largely replaced an older test (the Motulsky dye-decolouration test). Other possibilities are direct DNA testing and/or sequencing of the G6PD gene. The Beutler fluorescent spot test is a rapid and inexpensive test that visually identifies NADPH produced by G6PD under ultraviolet light. When the blood spot does not fluoresce, the test is positive; it can be falsely negative in patients who are actively hemolysing. It can therefore only be done 2–3 weeks after a hemolytic episode. When a macrophage in the spleen identifies an RBC with a Heinz body, it removes the precipitate and a small piece of the membrane, leading to characteristic "bite cells". However, if a large number of Heinz bodies are produced, as occurs in G6PD deficiency, some Heinz bodies will be visible when viewing RBCs stained with crystal violet. This easy and inexpensive test can lead to an initial presumption of G6PD deficiency, which can be confirmed with the other tests.
This process has also been observed in simulations of transthyretin and implicated as occurring naturally in certain protein families by examination of their dihedral angle conformations in crystal structures. It is suggested that alpha-sheet folds into multi-strand solenoids.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
多肽在反相柱上按疏水性差异分离，能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比，是肽类分析的常规手段。